News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
644,555 Results
Type
Article (55249)
Company Profile (162)
Press Release (589144)
Multimedia
Podcasts (91)
Webinars (11)
Section
Business (176780)
Career Advice (2967)
Deals (33925)
Drug Delivery (123)
Drug Development (77363)
Employer Resources (177)
FDA (16047)
Job Trends (14911)
News (315003)
Policy (34491)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (1)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (9)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (3)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2812)
Academic (2)
Accelerated approval (6)
Adcomms (26)
Allergies (84)
Alliances (51295)
ALS (96)
Alzheimer's disease (1430)
Antibody-drug conjugate (ADC) (133)
Approvals (16017)
Artificial intelligence (258)
Autoimmune disease (25)
Automation (14)
Bankruptcy (342)
Best Places to Work (11427)
BIOSECURE Act (21)
Biosimilars (114)
Biotechnology (109)
Bladder cancer (67)
Brain cancer (30)
Breast cancer (263)
Cancer (2106)
Cardiovascular disease (184)
Career advice (2483)
Career pathing (32)
CAR-T (154)
Cell therapy (415)
Cervical cancer (20)
Clinical research (62613)
Collaboration (815)
Compensation (440)
Complete response letters (30)
COVID-19 (2819)
CRISPR (42)
C-suite (208)
Cystic fibrosis (91)
Data (1998)
Decentralized trials (2)
Denatured (23)
Depression (49)
Diabetes (271)
Diagnostics (6447)
Digital health (19)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (122)
Drug pricing (119)
Drug shortages (32)
Duchenne muscular dystrophy (93)
Earnings (62742)
Editorial (41)
Employer branding (21)
Employer resources (152)
Events (86413)
Executive appointments (637)
FDA (17188)
Featured Employer (39)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (694)
Gene editing (102)
Generative AI (23)
Gene therapy (305)
GLP-1 (809)
Government (4878)
Grass and pollen (5)
Guidances (49)
Healthcare (18380)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (27)
Infectious disease (2974)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (55)
Intellectual property (93)
Interviews (562)
IPO (15523)
IRA (47)
Job creations (3884)
Job search strategy (2088)
Kidney cancer (9)
Labor market (33)
Layoffs (531)
Leadership (20)
Legal (9143)
Liver cancer (70)
Lung cancer (307)
Lymphoma (140)
Machine learning (4)
Management (61)
Manufacturing (300)
MASH (66)
Medical device (12442)
Medtech (12446)
Mergers & acquisitions (18903)
Metabolic disorders (720)
Multiple sclerosis (75)
NASH (21)
Neurodegenerative disease (105)
Neuropsychiatric disorders (31)
Neuroscience (1976)
NextGen: Class of 2025 (6536)
Non-profit (4677)
Northern California (2276)
Now hiring (27)
Obesity (395)
Opinion (264)
Ovarian cancer (75)
Pain (89)
Pancreatic cancer (80)
Parkinson's disease (147)
Partnered (20)
Patents (223)
Patient recruitment (98)
Peanut (49)
People (50799)
Pharmaceutical (40)
Pharmacy benefit managers (21)
Phase I (19025)
Phase II (27339)
Phase III (21404)
Pipeline (1119)
Policy (147)
Postmarket research (2545)
Preclinical (7960)
Press Release (68)
Prostate cancer (99)
Psychedelics (38)
Radiopharmaceuticals (250)
Rare diseases (377)
Real estate (5967)
Recruiting (69)
Regulatory (22603)
Reports (42)
Research institute (2479)
Resumes & cover letters (463)
Rett syndrome (4)
RNA editing (4)
RSV (47)
Schizophrenia (77)
Series A (118)
Series B (78)
Service/supplier (9)
Sickle cell disease (51)
Southern California (1945)
Special edition (17)
Spinal muscular atrophy (158)
Sponsored (31)
Startups (3563)
State (2)
Stomach cancer (14)
Supply chain (64)
Tariffs (20)
The Weekly (66)
United States (19851)
Vaccines (769)
Venture capitalists (37)
Weight loss (286)
Women's health (35)
Worklife (18)
Date
Today (47)
Last 7 days (441)
Last 30 days (2371)
Last 365 days (31453)
2025 (8362)
2024 (33470)
2023 (37949)
2022 (48856)
2021 (52952)
2020 (51920)
2019 (45790)
2018 (34885)
2017 (31975)
2016 (30895)
2015 (35495)
2014 (28599)
2013 (25056)
2012 (24895)
2011 (25475)
2010 (23009)
Location
Africa (958)
Alabama (48)
Alaska (5)
Arizona (165)
Arkansas (12)
Asia (39736)
Australia (6783)
California (5164)
Canada (1799)
China (488)
Colorado (235)
Connecticut (239)
Delaware (116)
Europe (91771)
Florida (809)
Georgia (186)
Hawaii (1)
Idaho (56)
Illinois (504)
India (24)
Indiana (267)
Iowa (7)
Japan (150)
Kansas (90)
Kentucky (21)
Louisiana (12)
Maine (68)
Maryland (808)
Massachusetts (3682)
Michigan (212)
Minnesota (293)
Mississippi (2)
Missouri (79)
Montana (26)
Nebraska (23)
Nevada (56)
New Hampshire (63)
New Jersey (1554)
New Mexico (30)
New York (1514)
North Carolina (904)
North Dakota (7)
Northern California (2276)
Ohio (190)
Oklahoma (11)
Oregon (32)
Pennsylvania (1180)
Puerto Rico (9)
Rhode Island (26)
South America (1321)
South Carolina (19)
South Dakota (1)
Southern California (1945)
Tennessee (82)
Texas (778)
Utah (177)
Virginia (139)
Washington D.C. (54)
Washington State (479)
West Virginia (3)
Wisconsin (43)
644,555 Results for "hoffmann la roche ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
Roche Makes Another Obesity Play With Potential $5.3B Amylin Pact With Zealand
Roche and Zealand plan to study petrelintide as a monotherapy and in combination with CT-388, a dual agonist of the GLP-1 and GIP receptors that Roche picked up in its recent acquisition of Carmot Therapeutics.
March 12, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children with one or more food allergies.
March 3, 2025
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
March 24, 2025
·
9 min read
Press Releases
RESTEM to Participate in Jones Las Vegas Technology and Innovation Conference
April 2, 2025
·
1 min read
Gene therapy
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
Roche acquired Spark Therapeutics in 2019 for $4.8 billion.
March 11, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Lyell Cuts 73 Employees as Part of LA Site Closure
After moving the manufacturing of a CAR T drug that was part of its ImmPACT Bio acquisition to Washington, Lyell Immunopharma is closing its Los Angeles manufacturing facility, eliminating dozens of jobs there.
April 7, 2025
·
1 min read
·
Angela Gabriel
Earnings
Roche to Stay ‘Disciplined’ With Deals in 2025
For 2025, Roche will continue a careful approach to high-priced deals, putting science at the center of its business development decisions, executives said Thursday.
January 30, 2025
·
2 min read
·
Tristan Manalac
Columvi (glofitamab for injection) receives positive CADTH and INESSS recommendations for adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL)
Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on March 5, 2024, the Institut National d’Excellence en Santé et en Services Sociaux (INESSS) recommended Columvi® (glofitamab for injection) for public reimbursement.
March 7, 2024
·
6 min read
Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for VABYSMO® (faricimab injection) for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
Hoffmann-La Roche Limited announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for VABYSMO®, indicated for the treatment of neovascular age-related macular degeneration and diabetic macular edema,1 two of the leading causes of vision loss among Canadians.
May 29, 2023
·
5 min read
1 of 64,456
Next
